A 12 month open-label randomized parallel group study to investigate the influence of salmeterol/fluticasone (50/500 BD [two times a day]) either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD [chronic obstructive pulmonary disease] (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage III+IV).

Trial Profile

A 12 month open-label randomized parallel group study to investigate the influence of salmeterol/fluticasone (50/500 BD [two times a day]) either in fixed combination or separately via Diskus inhalers on the course of the disease and frequency of exacerbations in subjects with severe and very severe COPD [chronic obstructive pulmonary disease] (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stage III+IV).

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2013

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms VIVESCO
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Jun 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Actual patient number (214) added as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top